ChemoMetec A/S (LON:0DZ0)

Market Cap	823.56M -22.5%
Revenue (ttm)	57.60M +7.3%
Net Income	20.68M +4.7%
EPS	1.19 +4.6%
Shares Out	n/a
PE Ratio	39.83
Forward PE	33.76
Dividend	0.82 (1.75%)
Ex-Dividend Date	Oct 10, 2025

Volume	5,006
Open	414.70
Previous Close	420.20
Day's Range	413.40 - 424.20
52-Week Range	236.00 - 799.25
Beta	1.36
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 172
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DZ0

Financial Performance

In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 17, 2026

Data Sources Report a data error